查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922980

醫用胰島素幫浦市場按幫浦類型、技術、糖尿病類型和通路分類－2026-2032年全球預測

Medical Insulin Pumps Market by Pump Type, Technology, Diabetes Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫用胰島素幫浦市場規模將達到 57.2 億美元，到 2026 年將成長至 62.3 億美元，複合年成長率為 9.19%，到 2032 年將達到 105.8 億美元。

關鍵市場統計數據
基準年 2025 57.2億美元
預計年份：2026年 62.3億美元
預測年份 2032 105.8億美元
複合年成長率 (%) 9.19%

一份簡明策略指南，旨在幫助經營團隊了解影響胰島素幫浦普及和採購趨勢的臨床、監管和商業性因素。

胰島素幫浦市場面臨來自臨床創新、不斷變化的監管環境以及患者偏好轉變的多重壓力，因此決策者需要全面的業務概覽。本文探討了在持續皮下胰島素輸注技術日趨成熟、與持續血糖監測系統整合度不斷提高以及對以患者為中心的易用性日益重視的背景下，胰島素幫浦的市場趨勢。隨著醫療系統和支付方將治療效果和成本效益置於優先地位，醫療設備功能、臨床通訊協定和報銷途徑之間的相互作用正成為住院和門診環境中採購和實施決策的關鍵促進因素。

閉合迴路技術的進步、患者的期望以及分銷模式的改變，正在從根本上改變胰島素治療的產品和市場推廣策略。

近年來，胰島素幫浦生態系統發生了許多變革性變化，這些變化正在重塑胰島素幫浦生態系統，並對產品、臨床和商業策略提出了新的要求。在技​​術方面，配備先進演算法和複雜閉合迴路功能的智慧胰島素幫浦日趨成熟，模糊了治療輸送和數位療法之間的界限，迫使製造商優先考慮軟體平台、網路安全和可互通的雲端生態系。隨著這種向互聯醫療的轉變，人們對數據準確性和分析能力的期望也越來越高，以支持個人化治療調整和人群健康監測。

評估2025年美國關稅調整將如何重塑胰島素幫相關人員的供應鏈結構、籌資策略和價格彈性。

美國將於2025年生效的新關稅制度進一步增加了全球胰島素幫浦供應鏈和相關人員商業性決策的複雜性。關稅調整將影響零件採購、組裝地點以及成品的最終落地成本，進而影響定價策略和利潤管理。這些變化迫使製造商重新評估其區域生產基地和供應商多元化計劃，以降低關稅波動帶來的風險，同時保持對醫療機構和零售買家的價格競爭力。

詳細的細分分析表明，設備外形、糖尿病分類、技術能力和通路各自決定了不同的採用率和服務需求。

細分市場分析揭示了每種設備形式、患者群體、嵌入式技術和分銷策略的不同機會和限制因素，因此需要量身定做的商業性和臨床方案。依泵浦類型分析，市場可分為貼片式和管式泵浦。貼片式幫浦更受注重隱蔽性和易用性的用戶青睞，而管式幫浦則更受胰島素需求量高或有其他臨床需求、需要連接硬體和更精確劑量控制的患者歡迎。這些差異會影響使用者培訓計劃、服務模式和保固結構。

區域比較和准入考量，重點介紹美洲、歐洲、中東和非洲以及亞太市場在臨床、監管和分銷方面的差異

區域趨勢正深刻影響胰島素幫相關人員的臨床實務模式、監管方式和商業性重點，每個宏觀區域都存在獨特的促進因素和限制因素。美洲的特點是專科醫療中心快速採用新技術，某些支付方群體高度重視基於價值的基本契約，以及蓬勃發展的數位健康整合生態系統支持遠距患者管理。這些因素雖然為先進的胰島素幫浦技術和生態系統合作創造了有利條件，但也帶來了激烈的競爭壓力，並提高了對上市後證據的期望。

競爭與合作的動態，透過平台整合、策略併購與價值主導的生態系統發展，塑造差異化策略。

胰島素幫浦市場的競爭格局日益受到硬體可靠性、軟體生態系統、數據整合能力和服務交付模式等因素相互作用的影響。現有設備製造商持續投資於平台級整合，將胰島素輸注硬體與血糖值監測、分析和醫療專業人員儀表板連接起來。同時，新參與企業則傾向於專注於諸如簡化使用者體驗、降低擁有成本和針對特定支付提案等細分優勢。設備公司與數位醫療公司之間的策略聯盟日益普遍，旨在加快先進功能的上市速度，並利用第三方在機器學習和使用者互動方面的專業知識。

製造商和醫療系統需要採取切實可行的策略措施，整合模組化創新、供應鏈韌性和以客戶為中心的服務模式

產業領導者應採取整合策略，在保障營運韌性和商業性柔軟性的同時，加速以病人為中心的創新。優先採用模組化產品架構，將核心交付機制與可升級的軟體元件分離，使供應商能夠迭代功能並快速部署監管更新。投資於互通性標準和開放API，可實現與醫院電子健康記錄、遠端監控平台和第三方分析解決方案的無縫整合，從而提高臨床應用率。

穩健的混合方法研究通訊協定，整合了專家訪談、證據三角驗證和情境分析，以確保分析的嚴謹性和實際相關性。

本執行摘要的調查方法整合了定性和定量數據，並透過結構化、透明的流程來最大限度地提高研究的有效性和可靠性。主要研究包括對臨床醫生、採購人員、支付方和行業高管的訪談，以了解他們對設備可用性、臨床整合和採購考慮等方面的真實觀點。在條件允許的情況下，我們會透過現場考察和設備可用性評估來補充這些訪談數據，從而驗證相關人員的認知與實際操作情況。

綜合分析揭示了技術、證據和營運韌性之間的關鍵交匯點，從而闡明了決定未來胰島素輸送成功與否的關鍵因素。

總之，胰島素幫浦市場環境正進入一個關鍵階段，技術能力、卓越服務和策略適應性將決定其長期成功。智慧幫浦技術和互通性的進步為改善臨床療效和患者生活品質提供了明確的機遇，但要實現這些益處，需要精心協調產品設計、證據產生和通路策略。關稅驅動的供應鏈重組和支付方期望的轉變，凸顯了營運韌性和透明價值溝通的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依幫浦類型分類的醫用胰島素幫浦市場

  • 補片泵浦
  • 管泵

9. 以技術分類的醫用胰島素幫浦市場

  • 傳統泵浦
  • 智慧泵浦

第10章 依糖尿病類型分類的醫用胰島素幫浦市場

  • 1型糖尿病
  • 2型糖尿病

第11章 依分銷管道分類的醫用胰島素幫浦市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 醫療胰島素幫浦市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 依組別分類的醫用胰島素幫浦市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國醫用胰島素幫浦市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國醫用胰島素幫浦市場

第16章：中國醫用胰島素幫浦市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AgVa Healthcare Pvt Ltd
  • AMF Medical SA
  • Becton Dickinson and Company
  • Beta Bionics, Inc.
  • Cane SpA
  • Debiotech SA
  • DreaMed Diabetes Ltd.
  • EOFlow Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • Medtronic plc
  • Medtrum Technologies
  • MicroPort Scientific Corporation
  • Smiths Group plc
  • SOOIL Development Co., Ltd.
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • ViCentra BV
  • Ypsomed AG
Product Code: MRR-867BED9A9E9C

The Medical Insulin Pumps Market was valued at USD 5.72 billion in 2025 and is projected to grow to USD 6.23 billion in 2026, with a CAGR of 9.19%, reaching USD 10.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.72 billion
Estimated Year [2026] USD 6.23 billion
Forecast Year [2032] USD 10.58 billion
CAGR (%) 9.19%

A concise strategic orientation for executives to understand clinical, regulatory, and commercial forces reshaping insulin pump adoption and procurement dynamics

The insulin pump market is experiencing convergent pressures from clinical innovation, regulatory evolution, and shifting patient preferences that demand an integrated executive overview for decision-makers. This introduction situates readers within a landscape defined by technological maturity in continuous subcutaneous insulin delivery, increasing integration with continuous glucose monitoring systems, and rising emphasis on patient-centered usability. As health systems and payers prioritize outcomes and cost-effectiveness, the interplay between device features, clinical protocols, and reimbursement pathways is becoming a primary driver of purchasing and adoption decisions across inpatient and outpatient settings.

Clinicians, procurement teams, and strategic planners require a concise framing of the core variables influencing adoption: device ergonomics, interoperability with digital platforms, lifecycle management and service models, and regulatory compliance across jurisdictions. These variables shape not only product development roadmaps but also distribution approaches and post-market surveillance strategies. The introduction clarifies the operational stakes for manufacturers and health-system partners alike, highlighting where near-term operational shifts can yield durable competitive advantage.

Finally, this section sets the tone for the subsequent analysis by establishing a common vocabulary for segmentation, regional dynamics, and competitive behavior. It underscores the need for evidence-driven decisions that balance clinical efficacy, patient experience, and commercial viability while preparing leaders to interpret deeper insights in the sections that follow.

How converging advances in closed-loop technology, patient expectations, and distribution models are fundamentally altering product and go-to-market strategies in insulin therapy

Recent years have seen several transformative shifts that are redefining the insulin pump ecosystem and creating new imperatives for product, clinical, and commercial strategy. At the technology level, the maturation of smart pumps with advanced algorithms and sophisticated closed-loop capabilities has blurred the lines between therapy delivery and digital therapeutics, prompting manufacturers to prioritize software platforms, cybersecurity, and interoperable cloud ecosystems. This movement toward connected care is accompanied by heightened expectations for data fidelity and analytics, which support personalized therapy adjustments and population health monitoring.

Concurrently, patient expectations are changing: a growing cohort of users is seeking discreet form factors and simplified workflows that reduce cognitive burden. This trend favors patch-style delivery systems while preserving the option for tubed pumps in more complex clinical scenarios. The distribution and service models are also shifting as online pharmacies and direct-to-consumer channels gain prominence alongside traditional hospital pharmacies and retail networks, necessitating new logistics, onboarding, and remote support capabilities.

Regulators and payers are increasingly focused on evidence generation that demonstrates real-world outcomes and cost-effectiveness. This emphasis has incentivized partnerships between device makers, academic institutions, and health systems to run pragmatic studies and registries. Taken together, these shifts are not isolated; they interact to create a landscape where agility in technology integration, human-centered design, and evidence-based commercialization are critical for sustained success.

Assessing how United States tariff adjustments in 2025 are reshaping supply chain configurations, sourcing strategies, and pricing resilience for insulin pump stakeholders

The introduction of new tariff regimes in the United States in 2025 has introduced another layer of complexity into the global supply chain and commercial calculus for insulin pump stakeholders. Tariff adjustments impact sourcing decisions for components, assembly locations, and the overall landed cost of finished systems, which in turn affects pricing strategies and margin management. These changes have prompted manufacturers to reassess regional manufacturing footprints and supplier diversification plans to mitigate exposure to tariff volatility and maintain competitive pricing structures for institutional and retail purchasers.

Beyond direct cost effects, tariff shifts influence strategic decisions about where to locate high-value activities such as software development, quality assurance, and final assembly. Companies with vertically integrated operations or near-shore partners have found opportunities to buffer tariff impacts, while those dependent on single-source international suppliers face greater pressure to redesign bills of materials or pursue alternative components. Additionally, reimbursement negotiations and procurement tenders may be more sensitive to price fluctuations; stakeholders must therefore strengthen cost-transparency efforts and provide robust clinical and economic evidence to sustain payer and provider relationships.

Operationally, supply chain resilience has become a focal point. Firms are accelerating dual-sourcing strategies, increasing inventory visibility, and investing in advanced planning systems to reduce lead-times and prevent stock disruptions. These adaptations are essential not only for commercial continuity but also for preserving patient access to essential insulin delivery technologies across care settings.

In-depth segmentation intelligence revealing how device form factors, diabetes classifications, technological capabilities, and channel pathways define distinct adoption and service imperatives

Segmentation analysis reveals nuanced opportunities and constraints across device formats, patient populations, embedded technologies, and channel strategies, each demanding tailored commercial and clinical approaches. When examined by pump type, the market differentiates between patch pumps and tubed pumps, with patch designs appealing to users prioritizing discretion and ease of use while tubed systems often serve patients with higher insulin requirements or clinical needs that benefit from tethered hardware and more granular dosing control. These distinctions influence user training programs, service models, and warranty structures.

Considering diabetes type, the needs of individuals with Type 1 Diabetes often emphasize automated insulin delivery and tighter glycemic control, whereas those with Type 2 Diabetes may prioritize simplicity, affordability, and incremental therapy intensification. This divergence affects messaging, clinical support pathways, and partnerships with endocrinology networks. From a technology perspective, the contrast between conventional pumps and smart pumps highlights differing value propositions: conventional pumps emphasize reliable mechanical delivery and cost-effectiveness, while smart pumps integrate decision-support, connectivity, and software-driven features that enable remote monitoring and data-driven therapy optimization.

Distribution channel dynamics further shape adoption. Hospital pharmacies remain central for inpatient and credentialed outpatient initiation, whereas online pharmacies present opportunities for direct consumer fulfillment and subscription models. Retail pharmacies deliver convenience and local support but require different stocking and education strategies. For manufacturers and channel partners, aligning product configurations, training curricula, and support services to the intersection of pump type, diabetes type, technology sophistication, and chosen distribution paths is essential for maximizing adoption and long-term adherence.

Comparative regional dynamics and entry considerations highlighting clinical, regulatory, and distribution nuances across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a strong influence on clinical practice patterns, regulatory approaches, and commercial priorities for insulin pump stakeholders, with each macro-region presenting distinct drivers and constraints. In the Americas, the ecosystem is characterized by rapid technology adoption among specialist centers, a strong emphasis on value-based contracting in select payer segments, and an active ecosystem of digital health integration that supports remote patient management. These factors create fertile ground for advanced pump technologies and ecosystem partnerships but also introduce intense competitive pressures and higher expectations for post-market evidence.

Across Europe, Middle East & Africa, the picture is heterogeneous: certain European markets emphasize strict health-technology assessments and centralized procurement processes that require robust cost-effectiveness data, while markets across the Middle East and Africa present opportunities for incremental access expansion, local partnerships, and tailored training initiatives to support decentralized care delivery. Regulatory harmonization efforts within the region can simplify market entry, but manufacturers still need to navigate localized reimbursement policies and supply chain challenges.

In the Asia-Pacific region, growth drivers include rising prevalence of diabetes, expanding private and public healthcare capacity, and a strong interest in mobile-enabled care models. However, success in these markets often depends on localized product customization, tiered pricing strategies, and partnerships with regional distributors and healthcare systems that can manage training and long-term patient support. Across all regions, aligning clinical evidence generation, regulatory pathways, and distribution strategies to regional realities is critical for sustainable market penetration and patient access.

Competitive and partnership dynamics shaping differentiation strategies through platform integration, strategic M&A, and value-driven ecosystem development

Competitive dynamics in the insulin pump landscape are increasingly defined by the interplay of hardware reliability, software ecosystems, data integration capabilities, and service delivery models. Established device manufacturers continue to invest in platform-level integration that links insulin delivery hardware with glucose sensing, analytics, and clinician-facing dashboards, while newer entrants often focus on niche advantages such as simplified user experience, lower cost of ownership, or specialized payer propositions. Strategic collaborations between device firms and digital health companies are becoming more commonplace as players seek to accelerate time-to-market for advanced features and leverage third-party expertise in machine learning and user engagement.

Partnerships and M&A activity are also reshaping competitive positioning. Companies are pursuing acquisitions that fill gaps in connectivity stacks, extend regulatory footprints, or add complementary distribution channels. In parallel, strategic alliances with healthcare systems, specialty pharmacies, and patient advocacy groups are proving valuable for establishing real-world registries and demonstrating long-term outcomes. Those firms that can demonstrate a coherent product-service ecosystem-combining robust hardware, intuitive software, reliable logistics, and outcomes evidence-are more likely to secure preferential placement in institutional formularies and payer-covered pathways.

Operational excellence remains a differentiator. Firms that invest in scalable manufacturing, regulatory rigor, and quality management systems while maintaining agile product development cycles are better positioned to respond to shifting clinical guidance and emergent cybersecurity requirements. For incumbents and challengers alike, the path to differentiation lies in delivering measurable clinical benefits alongside seamless user experiences and dependable support infrastructures.

Actionable strategic imperatives for manufacturers and health systems to align modular innovation, supply chain resilience, and customer-centric service models

Industry leaders should adopt an integrated playbook that accelerates patient-centric innovation while protecting operational resilience and commercial flexibility. Prioritizing modular product architectures that separate core delivery mechanics from upgradable software components will allow vendors to iterate features and deploy regulatory updates more rapidly. Investing in interoperability standards and open APIs can broaden clinical adoption by enabling seamless integration with hospital electronic medical records, remote monitoring platforms, and third-party analytics solutions.

Supply chain and manufacturing strategies must emphasize redundancy and geographic diversification to mitigate tariff and trade disruptions. Concurrently, commercial teams should develop differentiated value propositions for payers and providers that highlight not only clinical performance but also reductions in total cost of care through decreased hypoglycemia events, fewer emergency visits, and improved long-term outcomes. Providers will respond to clear evidence of clinical and operational benefit, so building pragmatic registries and real-world evidence programs that can be communicated in clinician-friendly formats is essential.

Finally, customer experience should be treated as a strategic priority: streamlined onboarding, accessible remote training, and responsive post-sale support underpin adherence and long-term retention. Leaders should also explore subscription and service-based pricing models that align incentives between manufacturers, payers, and health systems, enabling predictable revenue streams while lowering upfront barriers to access for patients and institutions.

Robust mixed-method research protocols integrating expert interviews, evidence triangulation, and scenario analysis to ensure analytical rigor and practical relevance

The research methodology underpinning this executive summary synthesizes qualitative and quantitative inputs through a structured, transparent process designed to maximize validity and reliability. Primary research comprises targeted interviews with clinicians, procurement leads, payers, and industry executives to capture real-world perspectives on device usability, clinical integration, and purchasing considerations. These interviews are supplemented by observational inputs from site visits and device usability assessments where feasible, enabling triangulation between stakeholder perceptions and operational realities.

Secondary research includes systematic review of regulatory guidance, clinical literature, patent filings, and public company disclosures to map technology roadmaps and compliance obligations. Evidence synthesis applies data triangulation techniques that reconcile insights from multiple sources and identify consistent themes and divergence points. Wherever possible, claims and interpretations are cross-validated against peer-reviewed clinical evidence and regulatory documentation to ensure factual accuracy and contextual relevance.

Analytical approaches include scenario analysis to explore the implications of tariff shifts and technology adoption trajectories, along with sensitivity testing of key operational assumptions. Expert advisory input has been leveraged throughout to challenge assumptions, validate findings, and ensure the final recommendations are practical and actionable for industry stakeholders.

Concluding synthesis identifying the critical intersections of technology, evidence, and operational resilience that will determine future success in insulin delivery

In conclusion, the insulin pump landscape is entering a phase where technological capability, service excellence, and strategic adaptability determine long-term success. Advances in smart pump technology and interoperability present clear opportunities to improve clinical outcomes and patient quality of life, yet realizing these benefits requires careful alignment of product design, evidence generation, and channel strategy. The combined effects of tariff-driven supply chain recalibration and shifting payer expectations underscore the importance of operational resilience and transparent value communication.

Stakeholders who prioritize modular architectures, invest in real-world outcomes programs, and build flexible distribution and support models will be better positioned to convert technological potential into sustained adoption. Likewise, collaborations across industry, healthcare providers, and digital health partners will accelerate the development of integrated solutions that address both clinical efficacy and patient experience. The path forward is not without complexity, but deliberate, evidence-driven strategies provide a clear route to advancing care while achieving commercial objectives.

Taken together, these conclusions point to a pragmatic agenda for leaders: focus on interoperable innovation, strengthen supply chain and value demonstration capabilities, and enhance customer experience to secure durable market relevance and improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Insulin Pumps Market, by Pump Type

  • 8.1. Patch Pumps
  • 8.2. Tubed Pumps

9. Medical Insulin Pumps Market, by Technology

  • 9.1. Conventional Pumps
  • 9.2. Smart Pumps

10. Medical Insulin Pumps Market, by Diabetes Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Medical Insulin Pumps Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Medical Insulin Pumps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Medical Insulin Pumps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Medical Insulin Pumps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Medical Insulin Pumps Market

16. China Medical Insulin Pumps Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AgVa Healthcare Pvt Ltd
  • 17.6. AMF Medical SA
  • 17.7. Becton Dickinson and Company
  • 17.8. Beta Bionics, Inc.
  • 17.9. Cane S.p.A.
  • 17.10. Debiotech S.A.
  • 17.11. DreaMed Diabetes Ltd.
  • 17.12. EOFlow Co., Ltd.
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Insulet Corporation
  • 17.15. Medtronic plc
  • 17.16. Medtrum Technologies
  • 17.17. MicroPort Scientific Corporation
  • 17.18. Smiths Group plc
  • 17.19. SOOIL Development Co., Ltd.
  • 17.20. Tandem Diabetes Care, Inc.
  • 17.21. Terumo Corporation
  • 17.22. ViCentra B.V.
  • 17.23. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL INSULIN PUMPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MEDICAL INSULIN PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)